1. Progesterone and its derivatives for the treatment of catamenial epilepsy: A systematic review.
- Author
-
Nucera, B., Rinaldi, F., Dono, F., Lanzone, J., Evangelista, G., Consoli, S., Tappatà, M., Narducci, F., Troisi, S., Trinka, E., and Brigo, F.
- Abstract
• Catamenial epilepsy is an increase in seizure frequency during or before menses. • Systematic review of progesterone and its derivatives for catamenial epilepsy. • There is no agreement on dose, duration, and pharmacological formulation. • Efficacy was not demonstrated in randomized controlled trials. • Further research and studies in this field are required. Catamenial epilepsy (CE) is defined as an increase in seizure frequency during specific phases of the menstrual cycle in women with epilepsy. The treatment usually includes a combination of non-hormonal and hormonal therapies. This systematic review summarizes the available data on the efficacy of progesterone and its derivates to treat CE. We performed a systematic search of the literature to identify studies reporting data on the use of progesterone and its derivatives (any type and dose) for the treatment of CE. The main outcome included the efficacy of progesterone and its derivatives on seizure frequency. Nineteen articles (457 patients) were included; four were randomized controlled trials (two comparing progesterone vs placebo and two comparing norethisterone vs placebo). Progesterone was generally administered during the luteal phase (from day 15 to 25) or during perimenstrual exacerbations (from day 23 to 25), with an average dose of 10–30 mg/day to a maximum of 300 mg/day. The therapy, usually well tolerated, was ineffective in the randomized controlled trials; conversely, it was associated with an overall reduction in seizure frequency in case reports and uncontrolled studies. Although data from uncontrolled studies suggest that hormone therapy with progesterone may be useful in the treatment of CE, its efficacy has not been demonstrated in controlled trials. The possible antiseizure effect of progesterone could be mediated by its active metabolite allopregnanolone, making the plasmatic measurement of these hormones mandatory to evaluate efficacy. Further randomized controlled trials should investigate the efficacy of progesterone and its derivatives, addressing these pharmacological issues. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF